menu
    • menu
    [{"orgOrder":0,"company":"Rambam Health Care Campus","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"ISRAEL","productType":"Miscellaneous","year":"2010","type":"Inapplicable","leadProduct":"Gentamicin Sulfate","moa":"Bacterial 70S ribosome","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Rambam Health Care Campus","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Rambam Health Care Campus \/ Undisclosed","highestDevelopmentStatusID":"1","companyTruncated":"Rambam Health Care Campus \/ Undisclosed"},{"orgOrder":0,"company":"Rambam Health Care Campus","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"ISRAEL","productType":"Hormone","year":"2020","type":"Inapplicable","leadProduct":"Oxytocin","moa":"Oxytocin receptor","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Rambam Health Care Campus","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Rambam Health Care Campus \/ Undisclosed","highestDevelopmentStatusID":"1","companyTruncated":"Rambam Health Care Campus \/ Undisclosed"},{"orgOrder":0,"company":"MigVax","sponsor":"Ourcrowd","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"ISRAEL","productType":"Vaccine","year":"2020","type":"Financing","leadProduct":"COVID-19 Vaccine","moa":"SARS-CoV-2","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"MigVax","amount2":0.01,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0.01,"dosageForm":"Undisclosed","sponsorNew":"MigVax \/ Ourcrowd","highestDevelopmentStatusID":"1","companyTruncated":"MigVax \/ Ourcrowd"},{"orgOrder":0,"company":"NanoPass Technologies","sponsor":"YNC Medical","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"ISRAEL","productType":"Vaccine","year":"2022","type":"Inapplicable","leadProduct":"Inactivated SARS-CoV-2 Vaccine","moa":"SARS-CoV-2 S","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"NanoPass Technologies","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"NanoPass Technologies \/ YNC Medical","highestDevelopmentStatusID":"1","companyTruncated":"NanoPass Technologies \/ YNC Medical"},{"orgOrder":0,"company":"Rambam Health Care Campus","sponsor":"Fondazione Policlinico Universitario Agostino Gemelli | Gazi University | University of Alberta | Imperial College London | University of Debrecen | Lithuanian University of Health Sciences","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"ISRAEL","productType":"Probiotic","year":"2023","type":"Inapplicable","leadProduct":"Fecal Microbiota","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Rambam Health Care Campus","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Rambam Health Care Campus \/ Fondazione Policlinico Universitario Agostino Gemelli | Gazi University | University of Alberta | Imperial College London | University of Debrecen | Lithuanian University of Health Sciences","highestDevelopmentStatusID":"1","companyTruncated":"Rambam Health Care Campus \/ Fondazione Policlinico Universitario Agostino Gemelli | Gazi University | University of Alberta | Imperial College London | University of Debrecen | Lithuanian University of Health Sciences"},{"orgOrder":0,"company":"Pluri","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"ISRAEL","productType":"Cell & Gene Therapy","year":"2020","type":"Inapplicable","leadProduct":"PLX Cell","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Pluri","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Pluri \/ Undisclosed","highestDevelopmentStatusID":"1","companyTruncated":"Pluri \/ Undisclosed"},{"orgOrder":0,"company":"Israel Institute for Biological Research","sponsor":"Dyadic International, Inc","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"ISRAEL","productType":"Vaccine","year":"2020","type":"Collaboration","leadProduct":"rVaccine","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Israel Institute for Biological Research","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Israel Institute for Biological Research \/ Dyadic International, Inc","highestDevelopmentStatusID":"1","companyTruncated":"Israel Institute for Biological Research \/ Dyadic International, Inc"},{"orgOrder":0,"company":"SuperTrans Medical","sponsor":"Mediforum Pharm","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"ISRAEL","productType":"Undisclosed","year":"2020","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"SuperTrans Medical","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"SuperTrans Medical \/ Mediforum Pharm","highestDevelopmentStatusID":"1","companyTruncated":"SuperTrans Medical \/ Mediforum Pharm"}]

    Find Clinical Drug Development Pipelines & Deals | PipelineProspector

    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Rambam Health Care Campus

                            Israel arrow
                            Florida Innovation
                            Not Confirmed

                            Rambam Health Care Campus

                            Israel arrow
                            Florida Innovation
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Fecal Microbiota

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Undisclosed

                            Sponsor : Fondazione Policlinico Universitario Agostino Gemelli | Gazi University | University of Alberta | Imperial College London | University of Debrecen | Lithuanian University of Health Sciences

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Lyophilized Fecal Microbiome Transfer vs. Vancomycin Monotherapy for Primary Clostridioides Difficile Infectio...

                            Details : Fecal Microbiota is a Probiotic drug candidate, which is currently being evaluated in clinical studies for the treatment of Clostridium Infections.

                            Product Name : Undisclosed

                            Product Type : Probiotic

                            Upfront Cash : Inapplicable

                            February 02, 2023

                            Lead Product(s) : Fecal Microbiota

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Undisclosed

                            Sponsor : Fondazione Policlinico Universitario Agostino Gemelli | Gazi University | University of Alberta | Imperial College London | University of Debrecen | Lithuanian University of Health Sciences

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            NanoPass Technologies

                            Israel arrow
                            Florida Innovation
                            Not Confirmed

                            NanoPass Technologies

                            Israel arrow
                            Florida Innovation
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Inactivated SARS-CoV-2 Vaccine

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Undisclosed

                            Sponsor : YNC Medical

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Nanopass’s Intradermal Injection Platform Proven to Sustain COVID-19 Vaccine Antibodies Using 1/15 of The Do...

                            Details : The results of IMB’s inactivated SARS-CoV-2 vaccine, have shown that the intradermal 3rd boost allowed for robust and sustained (>6mo) immunogenicity with a favorable safety (no fever and only mild injection site redness and swelling).

                            Product Name : Undisclosed

                            Product Type : Vaccine

                            Upfront Cash : Inapplicable

                            February 07, 2022

                            Lead Product(s) : Inactivated SARS-CoV-2 Vaccine

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Undisclosed

                            Sponsor : YNC Medical

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            Rambam Health Care Campus

                            Israel arrow
                            Florida Innovation
                            Not Confirmed

                            Rambam Health Care Campus

                            Israel arrow
                            Florida Innovation
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Hydroxychloroquine Sulphate

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Undisclosed

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Hydroxychloroquine Post-Exposure Prophylaxis for Coronavirus Disease (COVID-19) Among Health-Care Workers

                            Details : Hydroxychloroquine is a Other Small Molecule drug candidate, which is currently being evaluated in clinical studies for the treatment of COVID-19.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            June 19, 2020

                            Lead Product(s) : Hydroxychloroquine Sulphate

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Undisclosed

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            MigVax

                            Israel arrow
                            Florida Innovation
                            Not Confirmed

                            MigVax

                            Israel arrow
                            Florida Innovation
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : MigVax-101

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Undisclosed

                            Sponsor : Ourcrowd

                            Deal Size : $100.0 million

                            Deal Type : Funding

                            DEALS_DEV arrow-down

                            OurCrowd Launches $100 Million Pandemic Innovation Fund

                            Details : First investments to include MigVax - Israeli contender to produce oral coronavirus vaccine, and Sight Diagnostics - rapid, accurate and safe blood test technology in use at hospitals with COVID-19 patients.

                            Product Name : Undisclosed

                            Product Type : Vaccine

                            Upfront Cash : Undisclosed

                            June 02, 2020

                            Lead Product(s) : MigVax-101

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Undisclosed

                            Sponsor : Ourcrowd

                            Deal Size : $100.0 million

                            Deal Type : Funding

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            05

                            Kamada

                            Israel arrow
                            Florida Innovation
                            Not Confirmed

                            Kamada

                            Israel arrow
                            Florida Innovation
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Undisclosed

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Undisclosed

                            Sponsor : Kedrion

                            Deal Size : Undisclosed

                            Deal Type : Collaboration

                            DEALS_DEV arrow-down

                            Kamada and Kedrion Biopharma Join Hands to Develop, Manufacture and Distribute Plasma Based Anti-SARS-CoV-2 Po...

                            Details : Kedrion will supply plasma from convalescent COVID-19. Kamada will be responsible for development, manufacturing and distribution of the product in territories not under kedrion’s responsibility.

                            Product Name : Undisclosed

                            Product Type : Undisclosed

                            Upfront Cash : Undisclosed

                            April 27, 2020

                            Lead Product(s) : Undisclosed

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Undisclosed

                            Sponsor : Kedrion

                            Deal Size : Undisclosed

                            Deal Type : Collaboration

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            06

                            MigVax

                            Israel arrow
                            Florida Innovation
                            Not Confirmed

                            MigVax

                            Israel arrow
                            Florida Innovation
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : COVID-19 Vaccine

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Undisclosed

                            Sponsor : Ourcrowd

                            Deal Size : $12.0 million

                            Deal Type : Financing

                            DEALS_DEV arrow-down

                            OurCrowd Leads $12 Million Investment Round in Israeli COVID-19 Vaccine Company MigVax

                            Details : Investment will accelerate path to clinical trials and bring Israel’s human coronavirus vaccine to market.

                            Product Name : Undisclosed

                            Product Type : Vaccine

                            Upfront Cash : Undisclosed

                            April 22, 2020

                            Lead Product(s) : COVID-19 Vaccine

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Undisclosed

                            Sponsor : Ourcrowd

                            Deal Size : $12.0 million

                            Deal Type : Financing

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            07

                            RedHill Biopharma

                            Israel arrow
                            Florida Innovation
                            Not Confirmed

                            RedHill Biopharma

                            Israel arrow
                            Florida Innovation
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Opaganib,Hydroxychloroquine Sulphate

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Undisclosed

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Initial Data Shows Improvement In Covid-19 With Redhill’s Opaganib

                            Details : Opaganib was administered in addition to standard-of-care, including hydroxychloroquine background therapy, and was well tolerated.

                            Product Name : Yeliva

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            April 14, 2020

                            Lead Product(s) : Opaganib,Hydroxychloroquine Sulphate

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Undisclosed

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            08

                            SuperTrans Medical

                            Israel arrow
                            Florida Innovation
                            Not Confirmed

                            SuperTrans Medical

                            Israel arrow
                            Florida Innovation
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Undisclosed

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Undisclosed

                            Sponsor : Mediforum Pharm

                            Deal Size : $2.0 million

                            Deal Type : Collaboration

                            DEALS_DEV arrow-down

                            Korean firm invests $2M in SuperTrans Medical

                            Details : SuperTrans is completing a candidate evaluation of COVID-19 therapy based on its transmission technology.

                            Product Name : Undisclosed

                            Product Type : Undisclosed

                            Upfront Cash : Undisclosed

                            April 10, 2020

                            Lead Product(s) : Undisclosed

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Undisclosed

                            Sponsor : Mediforum Pharm

                            Deal Size : $2.0 million

                            Deal Type : Collaboration

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            09

                            Rambam Health Care Campus

                            Israel arrow
                            Florida Innovation
                            Not Confirmed

                            Rambam Health Care Campus

                            Israel arrow
                            Florida Innovation
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Oxytocin

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Undisclosed

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Management of Prelabor Rupture of the Membranes at Term

                            Details : Oxytocin is a Hormone drug candidate, which is currently being evaluated in clinical studies for the treatment of Infections.

                            Product Name : Undisclosed

                            Product Type : Hormone

                            Upfront Cash : Inapplicable

                            March 13, 2020

                            Lead Product(s) : Oxytocin

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Undisclosed

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            10

                            Pluri

                            Israel arrow
                            Florida Innovation
                            Not Confirmed

                            Pluri

                            Israel arrow
                            Florida Innovation
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : PLX Cell

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Undisclosed

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Pluristem and Charité University of Medicine Berlin Join Forces Targeting COVID-19 Treatment

                            Details : Pre-clinical findings of PLX cells revealed significant therapeutic effects in animal studies of pulmonary hypertension, lung fibrosis, acute kidney injury and gastrointestinal in COVID-19 infection.

                            Product Name : PLX Cell

                            Product Type : Cell & Gene Therapy

                            Upfront Cash : Inapplicable

                            March 12, 2020

                            Lead Product(s) : PLX Cell

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Undisclosed

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth